← FDA Drug Approvals (Drugs@FDA)

REGADENOSON

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: BAXTER HLTHCARE CORP · Approved 2023-05-23

Drug application

FDA Application #

ANDA217455

Application type

Abbreviated New Drug Application (Generic)

Brand name

REGADENOSON

Generic name

REGADENOSON

Active ingredients

REGADENOSON

Dosage form

SOLUTION

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

BAXTER HLTHCARE CORP

Manufacturer

Baxter Healthcare Corporation

First approval

2023-05-23

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown